EGFR and ovarian serous cystadenocarcinoma: Only EGFR was significantly correlated with poor outcome (HR = 1.51, 95% CI 1.15–2, P = 0.0033) in ovarian serous cystadenocarcinoma, whereas SIRT1 predicted a good outcome (HR = 0.75, 95% CI 0.57–1, P = 0.047).